Provided by Tiger Trade Technology Pte. Ltd.

Allogene Therapeutics Inc.

1.74
+0.00500.29%
Volume:2.40M
Turnover:4.15M
Market Cap:598.58M
PE:-2.67
High:1.76
Open:1.73
Low:1.70
Close:1.73
52wk High:4.46
52wk Low:1.04
Shares:345.00M
Float Shares:262.00M
Volume Ratio:0.90
T/O Rate:0.92%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.6510
EPS(LYR):-0.8652
ROE:-42.39%
ROA:-22.08%
PB:1.37
PE(LYR):-2.01

Loading ...

BUZZ-U.S. STOCKS ON THE MOVE-Nike, PNC Financia, OSI Systems

Reuters
·
Apr 16

Unusually active option classes on open April 15th

TIPRANKS
·
Apr 15

Allogene enrolls Phase 1 RESOLUTION trial of ALLO-329 in autoimmune diseases

Reuters
·
Apr 15

Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

GlobeNewswire
·
Apr 15

BRIEF-Allogene Therapeutics Announces Pricing Of Public Offering Of Common Stock

Reuters
·
Apr 15

Allogene prices 87,500,000-share follow-on offering at $2 per share

Reuters
·
Apr 15

Allogene Therapeutics Inc - Prices Public Offering of 87,500,000 Shares at $2.00 per Share

THOMSON REUTERS
·
Apr 15

Top Midday Decliners

MT Newswires Live
·
Apr 15

Canaccord Genuity Keeps Their Buy Rating on Allogene Therapeutics (ALLO)

TIPRANKS
·
Apr 14

Bernstein Sticks to Their Hold Rating for Allogene Therapeutics (ALLO)

TIPRANKS
·
Apr 14

Allogene Therapeutics Shares Down 5.2% Premarket After Co Announces $175 Mln Stock Offering Plans

THOMSON REUTERS
·
Apr 14

NASD Most Active Issues

Dow Jones
·
Apr 14

Allogene Therapeutics Announces Proposed Public Offering Of $175 Million Of Common Stock

Reuters
·
Apr 14

BUZZ-Allogene slips on $175 mln stock offering plans after blood cancer study

Reuters
·
Apr 14

Cellectis highlights Allogene ALPHA3 trial data, potential milestone payments

TIPRANKS
·
Apr 14

Allogene Therapeutics Inc - Offering $175 Mln of Common Stock - SEC Filing

THOMSON REUTERS
·
Apr 14

Allogene Therapeutics plans $175 million common stock offering

Reuters
·
Apr 14

Allogene Therapeutics Inc - Net Proceeds Expected to Be Used for General Corporate Purposes Including Clinical Trials and R&D

THOMSON REUTERS
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Conagra, Oracle, Replimune

Reuters
·
Apr 14

BUZZ-U.S. STOCKS ON THE MOVE-Allogene Therapeutics, Adobe, Williams-Sonoma

Reuters
·
Apr 13